Skip to Content

Cassava Sciences Inc SAVA

Morningstar Rating
$20.43 +0.02 (0.10%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SAVA is trading at a 43% discount.
Price
$19.85
Fair Value
$17.16
Uncertainty
Extreme
1-Star Price
$736.13
5-Star Price
$1.89
Economic Moat
Tbyj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SAVA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$20.41
Day Range
$20.2020.54
52-Week Range
$12.3332.05
Bid/Ask
$20.33 / $20.44
Market Cap
$883.51 Mil
Volume/Avg
48,783 / 715,558

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
29

Comparables

Valuation

Metric
SAVA
AVXL
CERE
Price/Earnings (Normalized)
Price/Book Value
6.273.0611.41
Price/Sales
Price/Cash Flow
Price/Earnings
SAVA
AVXL
CERE

Financial Strength

Metric
SAVA
AVXL
CERE
Quick Ratio
8.6011.7910.81
Current Ratio
9.1311.8510.92
Interest Coverage
−44.07
Quick Ratio
SAVA
AVXL
CERE

Profitability

Metric
SAVA
AVXL
CERE
Return on Assets (Normalized)
−47.53%−21.26%−38.51%
Return on Equity (Normalized)
−51.26%−23.17%−84.00%
Return on Invested Capital (Normalized)
−55.59%−27.24%−49.36%
Return on Assets
SAVA
AVXL
CERE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSbffyhkyHjhpw$571.0 Bil
VRTX
Vertex Pharmaceuticals IncTfdpzyscXygdmr$107.8 Bil
REGN
Regeneron Pharmaceuticals IncQqbwxvqsqMxgpsm$106.1 Bil
MRNA
Moderna IncFrlbrflqWrn$42.3 Bil
ARGX
argenx SE ADRJzwrqkfjzSddwt$23.7 Bil
BNTX
BioNTech SE ADRSlbfnxmgMbtdb$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncRvqjxyxFpfskqg$19.4 Bil
BMRN
Biomarin Pharmaceutical IncJhmhlfyxThxwbwl$16.7 Bil
RPRX
Royalty Pharma PLC Class AWqtcfmgrnGzmzyd$13.6 Bil
INCY
Incyte CorpLtzqrkzCzsvyg$12.8 Bil

Sponsor Center